Objective: Premature saccades (PSs) are those made with latencies too short for the direction and amplitude to be specifically programmed. We sought to determine the minimum latency needed to establish accurate direction and amplitude, and observed what occurs when saccades are launched before this minimum latency., Methods: In Experiment 1, 249 normal subjects performed the gap saccade task with horizontal targets. In Experiment 2, 28 normal subjects performed the gap saccade task with the targets placed in eight directions. In Experiment 3, 38 normal subjects, 49 patients with Parkinson's disease (PD), and 10 patients with spinocerebellar degeneration (SCD) performed the gap saccade task with horizontal targets., Results: In Experiment 1, it took 100 ms to accurately establish saccade amplitudes and directions. In Experiment 2, however, the latencies needed for accurate amplitude and direction establishment were both approximately 150 ms. In Experiment 3, the frequencies of PSs in patients with PD and SCD were lower than those of normal subjects., Conclusions: The saccade amplitudes and directions are determined simultaneously, 100-150 ms after target presentation. PSs may result from prediction of the oncoming target direction or latent saccade activities in the superior colliculus., Significance: Saccade direction and amplitude are determined simultaneously., Competing Interests: Conflict of interest statement Dr. Tokushige was supported by a Research Project Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (19 K17046), and has received a speaker’s honoraria from Otsuka Pharmaceutical Co., Ltd. Dr. Hamada was supported by MEXT KAKENHI (Nos. 15 K19476, 15H01658, 16H01605, and 18 K07521). Dr. Ugawa received grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Nos. 25293206, 15H05881,16H05322, and 18 K10821), The Research Committee on the Medical Basis of Motor Ataxias, Health and Labor Science Research Grants, the Ministry of Health, Labor and Welfare of Japan, the Support Center for Advanced Telecommunications Technology Research, the Association of Radio Industries Businesses, and the Novartis Foundation (Japan) for the Promotion of Science, Nihon Kohden, Ltd., Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co.,Ltd., Mitsubishi Tanabe Pharma Corporation. Dr Ugawa received honoraria from the Taiwan Movement Disorders Society, Chinese Neurology Society, Astellas Pharma Inc., Eisai Co.,Ltd., FP Pharmaceutical Corporation, Otsuka Pharmaceutical Co.,Ltd., Elsevier Japan K.K., Kissei Pharmaceutical Co.,Ltd., Kyorin Pharmaceutical Co.,Ltd., Kyowa Hakko Kirin Co.,Ltd., GlaxoSmithKline K.K., Sanofi-Aventis K.K., Daiichi Sankyo Co.,Ltd., Dainippon Sumitomo Pharma Co.,Ltd., Takeda Pharmaceutical Co.,Ltd., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Ltd., Nippon Chemiphar Co.,Ltd., Nihon Pharmaceutical Co.,Ltd., Nippon Boehringer Ingelheim Co.,Ltd., Novartis Pharma K.K., Bayer Yakuhin, Ltd., and Mochida Pharmaceutical Co.,Ltd. and received royalties from Chugai-Igakusha, Igaku-Shoin Ltd., Medical View Co.Ltd., and Blackwell Publishing K. K. Dr. Terao was supported by a Research Project Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (18H05523)., (Copyright © 2020 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.)